Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1550

Intravenous Oxygen

Inventors: John Kheir, Mark Borden, Francis McGowan

Invention Types: Therapeutics

Research Areas: Cardiovascular/Cardiology, Neonatology/Pediatric

Keywords: Patient Care, Polymer

For More Information Contact:  Khunkhun, Rajinder

 

Invention Description:

Dr. John Kheir and colleagues have developed a platform technology that packages oxygen in microbubbles for direct delivery via injection to blood and tissues. This technology is platform in nature and could revolutionize the practice of critical care medicine. An early and promising application is in treatment of patients who have undergone a myocardial infarction and experience cardiac arrest. The ability to keep blood oxygenated for even a short period of time under cardiac arrest circumstances or other circumstances in which a patient is unable to breathe or has no blood flow can prevent the tissue damage, including brain damage, that results from lack of oxygen.

Applications:

Critial care; hypoxia of any cause:
Cardiac arrest
Lung injury, lung disease
Airway obstruction
Traumatic brain injury
Birth asphyxia

Competitive Advantages:

There is currently no way to oxygenate blood via injection. Particularly for cardiac arrest, current methods all depend on circulating blood. This technology has the potential to deliver oxygen to the deoxygenated heart tissue quickly and directly, providing it with essential metabolic energy.

Business Opportunity:

Platform technology could be the basis for a start-up company. This technology could potentially be deployed in every ambulance, every operating room and every emergency room, and represents a large market opportunity.

Key Publications: Swanson EJ, et al. Phospholipid-stabilized microbubble foam for injectable oxygen delivery. Langmuir. 2010 Oct 19;26(20):15726-9.

Kheir JN, et al. Oxygen gas-filled microparticles provide intravenous oxygen delivery. Sci Transl Med. 2010 Jun 27;4(140):140ra88.

Kheir JN, et al. Bulk manufacture of concentrated oxygen gas-filled microparticles for intravenous oxygen delivery. Adv Healthc Mater. 2013 Aug;2(8):1131-41.

Seekell RP, et al. Oxygen delivery using engineered microparticles. Proc Natl Acad Sci USA. 2016 Nov 1;113(44):12380-5.

Seekell RP, et al. Tunable polymer microcapsules for controlled release of therapeutic gases. Langmuir. 2018 Aug 7;34(31):9175-83.

Related Publications: https://vector.childrenshospital.org/2016/11/intravenous-oxygen-delivery-edges-toward-the-clinic/

https://www.youtube.com/watch?v=R6OOWqdjaeA

IPStatus: Patented